This site is intended for healthcare professionals only
Three pharmaceutical companies exchanged commercially sensitive information to keep prices of antidepressant nortriptyline high, a government watchdog has alleged.
Manufacturer King Pharmaceuticals, along with wholesalers Alissa Healthcare and Lexon UK, exchanged commercially sensitive information, including information on prices, volumes and “entry plans...to try to keep nortriptyline prices high”, the Competition and Markets Authority (CMA) alleged yesterday (June 18).
Register to gain full access to C+D and C+D Community content
Already registered?
Already registered?
1Due to shortages in coal tar scalp ointment, the DHSC has asked the manufacturer of an equivalent product - Sebco - to provide increased stock levels to support patients during this time.
0Pharmacies in Scotland have been asked to ensure they have the “appropriate stock” of naloxone – a medicine used to reverse the effects of an opiate overdose – following an “increase in sudden collapse” due to overdoses.
5As the dust settles on the announcement that NHS England (NHSE) is set for the scrapheap, questions on what a 50% headcount cut means for local commissioners remain…
Walgreens Boots Alliance (WBA) has “entered into a definitive agreement to be acquired” by private equity firm Sycamore Partners.
Jhoots Chemist’s accounts for 2024 have revealed an almost £2 million year-on-year dip in shareholder funds – as debts to creditors increase more than £2m.
